CD4 monoclonal antibody administration in atopic dermatitis - 11/09/11
Abstract |
Background: Atopic dermatitis (AD) is a chronic inflammatory dermatosis that probably involves a dysregulated activation of helper T cells, type 2 (Th2 cells). Severe refractory AD can be controlled by cyclosporine treatment.
Objective: We attempted to determine whether short-term CD4 monoclonal antibody (mAb) therapy could improve severe AD in adults.
Methods: The CD4 mAb, B-F5, was infused over 2 days in three patients with severe refractory AD and, for control purposes, in two patients with severe psoriasis.
Results: Administration of B-F5 was well tolerated, despite moderate first dose side effects. Clinical improvement was observed in two patients. In the third patient, a dramatic worsening occurred between 8 and 30 days after treatment, associated with an increased percentage of activated CD4 + , CD25 + , HLA-DR + , and CD45RO + cells and peripheral blood eosinophilia. The same CD4 mAb administered to two patients with severe psoriasis induced marked clinical improvement of the lesions.
Conclusion: Although CD4 mAb infusion may be potentially useful in the treatment of AD, the risk of aggravating the Th1/Th2 imbalance in AD should be considered in the design of future protocols.
(J Am Acad Dermatol 1997;36:582-8.)
Le texte complet de cet article est disponible en PDF.Plan
From the Laboratory of Immunology,a the Department of Dermatology,b and the Immunotherapy Unit,c Lyon; Diaclone, Besançon,d and the Laboratory of Immunology, Centre Hospitalier Lyon Sud Jules Courmont.e |
|
Supported by the Institut National de la Santé et de la Recherche Médicale and by additional grants from the European Biotech Project "In vitro Immunotoxicology" (Bio 2. CT 92-0316) and Région Rhône-Alpes (HO98730000). |
|
Reprint requests: J. P. Revillard, MD, Hôpital Edouard Herriot, Pav. P, 69437 Lyon Cedex 3, France. |
|
0190-9622/97/$5.00 + 0 16/1/78474 |
Vol 36 - N° 4
P. 582-588 - avril 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?